Kendal Nutricare Limited will be referred to government and state agencies after refusing to participate in a compliance inquiry by the BBB National Programs’ National Advertising Division. The inquiry followed a challenge by Abbott Laboratories regarding Kendamil Infant Formula advertising claims about milk content and brand heritage. Kendal had agreed to some changes previously but declined further participation, prompting the referral for possible enforcement action. This move highlights regulatory scrutiny on truthful advertising in the infant formula market.
As of Nov 06, 2026 22:12 WIB, Abbott Laboratories (ABT) shares are trading at USD 111.35 on Pluang, down 1.98% for the day. The stock shows a high level of sell activity with 92% of orders on Pluang being sell orders. Abbott's market capitalization stands at $196.75 billion, highlighting its significant presence in the health sector.
Abbott announced one-year results from the VERITAS study showing its Amulet 360 Left Atrial Appendage Occluder achieved a 96.3% complete closure rate of the left atrial appendage in patients with non-valvular atrial fibrillation. The device also demo...
Abbott announced positive 30-day results from the TECTONIC study of its investigational SonicForce Coronary Intravascular Lithotripsy (IVL) System, which uses acoustic waves to break calcium in coronary arteries. The study of 335 patients met safety ...
